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Abstract
Despite recent advances in the treatment of multiple myeloma (MM), it remains an incurable disease potentially due to the
presence of resistant myeloma cancer stem cells (MM-CSC). Although the presence of clonogenic cells in MM was described
three decades ago, the phenotype of MM-CSC is still controversial, especially with respect to the expression of syndecan-1
(CD138). Here, we demonstrate the presence of two subpopulations - CD138++ (95–99%) and CD138low (1–5%) - in eight MM
cell lines. To find out possible stem-cell-like features, we have phenotypically, genomic and functionally characterized the
two subpopulations. Our results show that the minor CD138low subpopulation is morphologically identical to the CD138++
fraction and does not represent a more immature B-cell compartment (with lack of CD19, CD20 and CD27 expression).
Moreover, both subpopulations have similar gene expression and genomic profiles. Importantly, both CD138++ and
CD138low subpopulations have similar sensitivity to bortezomib, melphalan and doxorubicin. Finally, serial engraftment in
CB17-SCID mice shows that CD138++ as well as CD138low cells have self-renewal potential and they are phenotypically
interconvertible. Overall, our results differ from previously published data in MM cell lines which attribute a B-cell
phenotype to MM-CSC. Future characterization of clonal plasma cell subpopulations in MM patients’ samples will guarantee
the discovery of more reliable markers able to discriminate true clonogenic myeloma cells.
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Introduction
Multiple myeloma (MM) is characterized by the accumulation
of malignant plasma cells (PCs) in the bone marrow. Despite
recent advances in therapy that contributed to double patients’
survival [1], MM remains an incurable disease which may
potentially be explained, at least in part, to the persistence of
resistant MM cancer stem cells (MM-CSC) with clonogenic
potential. The presence of clonogenic cells in MM was described
more than 30 years ago [2], but the phenotype of this population is
still a matter of debate. It is well known that syndecan-1 (CD138),
a heparan sulfate proteoglycan, is expressed by both normal and
malignant PCs in most of MM patient samples and cell lines
[3,4,5], while absent on all earlier B-cells [5,6,7,8]. Interestingly,
some authors have described the presence of potential MM-CSC
that lacked expression of CD138 both in MM cell lines and patient
samples [9,10,11]. However, other studies have also demonstrated
that CD138+ PCs are clonogenic and can engraft in different mice
models [12,13,14]. It has also been reported that the tumor
microenvironment enhances the clonogenicity of human myeloma
cells and promotes their de-differentiation towards a more CD138
negative phenotype [15,16]. Therefore, whether MM-CSCs are
CD138+ or CD1382 is still controversial and multiple factors
could be implicated in this particular phenotype. Moreover, it has
been recently suggested that the CD1382 MM subpopulation
seems to represent an apoptotic artifact due to sample handling
and procedures [17]. In the present study, we have analyzed eight
MM cell lines and we have observed that all of them contain a
minor subpopulation of CD138low cells. Overall, our results show
that the subpopulation of CD138low cells does not differ from the
major CD138++ subpopulation regarding phenotypic, genomic
and functional features.
Materials and Methods
Ethics statement
All animal experiments were conducted according to Institu-
tional Guidelines for the Use of Laboratory Animals of the
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University of Salamanca (Spain), after acquiring permission from
the Bioethics Committee of the University of Salamanca, Spain
(Reg. Nu 201100030128) and in accordance with current Spanish
laws on animal experimentation (RD53/2013).
Reagents and immunochemicals
Cell-culture media, serum, and penicillin-streptomycin were
purchased from Invitrogen (Carlsbad, CA). Bortezomib was
provided by Millennium Pharmaceuticals (Cambridge, MA) and
melphalan and doxorubicin were obtained from Sigma-Aldrich (St
Louis, MO). Annexin-V–FITC was purchased from Immunostep
(Salamanca, Spain). May-Gru¨nwald and Giemsa stains were
obtained from Merck (Darmstadt, Germany). The origin of the
antibodies used in immunocytochemistry and flow cytometry was as
follows: anti-CD138-APC (clone B-B4), used for immunocytochem-
istry and flow cytometry, from Miltenyi Biotec (Auburn, CA); anti-
CD20-FITC (clone L27), anti-CD138-PerCP-Cy5 (clone MI15),
anti-CD56-APC (clone NCAM16.2), anti-CD45-AmCyan (clone
2D1) and anti-CD38-PE (clone HB7) from BD Biosciences (San
Jose, CA, USA); anti-CD19-PacificBlue (clone HIB19) and anti-
CD27-PE-Cy7 (clone O323) antibodies from eBioscience (San
Diego CA, USA); anti-CD38-AlexaFluor700 antibody (clone HIT2)
from Exbio (Vestec, Czech Republic) and anti-CD138-FITC (clone
B-A38) from Cytognos S.L. (Salamanca, Spain). The FITC anti-Ki-
67 Set was purchased from BD Biosciences (San Diego, CA) and
DRAQ5H was obtained from Biostatus (Leicestershire, UK).
Cell lines, cell culture and morphological characterization
The multiple myeloma cell lines used were: MM1S and MM1R
(from Dr. S. T. Rosen, Northwestern University, Chicago, IL)
[18]; NCI-H929 (from Dr. J. Teixido´, Centro de Investigaciones
Biolo´gicas, Madrid, Spain) [19] and RPMI-8226, U266, RPMI-
LR5, U266-LR7 and U266-Dox4 (from Dr. W.S. Dalton, Moffitt
Cancer Center, Tampa, FL) [20,21]. Briefly, cells were cultured in
RPMI-1640 medium supplemented with 2 mM L-glutamine,
100 U/mL penicillin, 100 mg/mL streptomycin and 10% fetal
bovine serum at 37uC and 5% CO2/95% air. Morphological
characterization of CD138++ and CD138low myeloma cells was
performed with May-Gru¨nwald-Giemsa staining.
Fluorescence-activated cell sorting and flow cytometry
MM cell lines were immunophenotyped on a FACSCanto II
cytometer (Becton Dickison Biosciences) using a 7-color immuno-
fluorescence technique [22] with the following combination of
monoclonal antibodies (Pacific Blue (PB)/anemonia majano cyan
(AmCyan)/fluorescein isothiocyanate (FITC)/peridinin chloro-
phyllprotein-cyanin 5.5 (PerCP-Cy5.5)/PE-cyanin 7 (PE-Cy7)/
allophycocyanin (APC)/alexafluor 700 (AF700)): CD19/CD45/
CD20/CD138/CD27/CD56/CD38. Data analysis was per-
formed using the Infinicyt software (Cytognos S.L.). CD138++
and CD138low cells were sorted on a FACSAria cytometer (BD
Biosciences) after incubation with CD138-APC plus 7AAD.
Sorting was performed exclusively on viable cells (7AAD2),
excluding debris by scatter properties and gating on the lowest
and highest 5% CD138-expressing cells. The CD138++ and
CD138low sorted cells had a final purity .95% (Figure S1). In
Figure 1. CD138 expression in MM cell lines. (A) Dot plots showing the percentage of CD138++ and CD138low cells in MM cell lines. (B) Top:
summary of the expression of CD19, CD20, CD27, CD38, CD45 and CD56 in CD138++ and CD138low subpopulations in MM cell lines. Code: –
(negative); 2/+ (heterogeneity); dim (weak positive); + (positive); ++ (high positive). Bottom: representative dot plots corresponding to non-stained
RPMI-8226 cells (negative control; light grey) and stained CD138++ (black) and CD138low (dark grey) RPMI-8226 cells. (C) Expression of CD138 by real-
time quantitative PCR in CD138++ and CD138low RPMI-8226 subpopulations. Relative values were calculated by the 22DCt method
(DCt = Ct(Gene)2Ct(GAPDH)). The GAPDH gene was used as a control gene. Results are expressed as the means 6 SEM (n = 3). (D–K) Confocal
images corresponding to the immunocytochemistry for CD138 (red) in CD138++ and CD138low RPMI-8226 and NCI-H929 cells. Nuclear DNA was
stained with DAPI (blue). Magnification of the lens, 63x. Specific ‘‘46 zoom’’ was made in E, G, I, K.
doi:10.1371/journal.pone.0092378.g001
Figure 2. Copy number abnormalities analysis of CD138++ and CD138low cells. Log ratio plot of all chromosomes corresponding to CD138++
RPMI-8266 cells (n = 3; left panel) and CD138low RPMI-8266 cells (n = 3; right panel) on the basis of Cytoscan HD array generated with Nexus.
doi:10.1371/journal.pone.0092378.g002
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some experiments the phenotype of the sorted populations was re-
analyzed after their expansion in vitro. Thus, either CD138++ or
CD138low RPMI-8226 cells were single-sorted into 96 multiwell
plates (1 cell/well) and serially expanded into 48, 24 and 12
multiwell plates for 25 up to 37 days. Afterwards, the phenotype of
each clone was analyzed by flow cytometry using CD138-APC
plus 7AAD. Apoptosis was determined by double staining with
CD38-PE plus CD138-APC followed by incubation with Annexin-
V-FITC/7AAD. To analyze the expression of Ki-67 in CD138++
and CD138low populations, cells were first surface-stained with
CD138-APC. Afterwards, they were fixed and permeabilized with
the Cytofix/CytopermTM Fixation/Permeabilization Solution Kit
(BD Biosciences) and then stained either with Ki-67-FITC or
isotype control. To analyze the cell cycle, cells were first incubated
with CD138-FITC followed by DRAQ5H and measured on a
FACSCanto II cytometer. The expression of aldehyde dehydro-
genase (ALDH) was assessed using the Aldefluor Kit (StemCell
Technologies, Grenoble, France) following the manufacturer’s
instructions with further staining with CD138-PerCP-Cy5.
Immunocytochemistry
After FACS sorting, cells were collected, washed with PBS,
centrifuged at 800 g for 3 minutes and then resuspended in 200 ml of
PBS. An aliquot was taken from each sample and placed on glass
slides coated with poly-L-lysine followed by 15 minutes incubation in
a cell culture incubator. Then, cells were fixed with 4% parafor-
maldehyde for 30 minutes, blocked with BSA 100 mg/ml for 1 h at
room temperature and incubated with anti-CD138-APC (1:100)
overnight at 4uC. Glass slides were then mounted using VECTA-
SHIELD Mounting Medium (Vector Laboratories, Burlingame,
CA). Finally, images were collected under Zeiss confocal microscope
equipped with 636/1.4 Oil Plan-APOCRHOMAT DIC.
Real time quantitative PCR (qRT-PCR)
Total RNA was extracted from CD138++ and CD138low
myeloma cells using an RNeasy Mini Kit (Qiagen, Valencia,
USA) following the manufacturer’s protocol. RNA quality and
quantity were assessed with the RNA Nano LabChip (Agilent
Tech. Inc., Palo Alto, CA, USA). The retrotranscription reaction
was performed using SuperScriptTM III First-Strand Synthesis
SuperMix (Invitrogen) according to the manufacturer’s recom-
mendations. Finally, qRT-PCR was performed to detect the target
gene (SDC1) using iQTM SYBR GreenSupermix kit (BioRad).
SYBR green qRT-PCR was performed using Bio-Rad iQ5 PCR
detection system with the following gene-specific primers: GAPDH,
forward 59-CAGGGCTGCTTTTAACTCTGGTAA-39 and re-
verse 59-GGGTGGAATCATATTGGAACATGTA-39; SDC1,
forward 59-GGCTGTAGTCCTGCCAGAAG-39 and reverse
59-GTTGAGGCCTGATGAGTGGT-39. Relative gene expres-
sion was calculated by the 22DCt method, DCt=Ct (gene)2Ct
(GAPDH).
Cell viability assay
Viability of multiple myeloma cells was assessed using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) col-
orimetric assay as previously described [23]. Briefly, CD138++ or
CD138low RPMI-8226 sorted cells were plated into 96-well culture
dishes (20000 cells/well) in the absence (control) or presence of
10 nM bortezomib, 10 mM melphalan or 250 nM doxorubicin
and incubated for 24 and 48 hours.
Microarray RNA analyses
RNA was isolated from CD138++ (n = 3) and CD138low (n = 3)
RPMI-8226 cells using an RNeasy Mini Kit (Qiagen, Valencia,
USA) following the manufacturer’s protocol. RNA was hybridized
to Human Gene 1.0 ST array (Affymetrix) according to Affymetrix
protocols [24]. Microarray data were normalized using the Robust
Multichip Analysis (RMA) algorithm implemented in the Affyme-
trix Expression Console. Data analysis was carried out using
DNA-Chip Analyzer software (DChip). The comparison criteria
used in DChip analysis were fold change E/B$2 or B/E$2, mean
difference E-B.100 or B-E.100 and the lower 90% confidence
bound of fold-change was used. All microarray data have been
deposited with the Gene Expression Omnibus (http://www.ncbi.
nlm.nih.gov/geo/; accession number GSE49482).
Identification of IGH rearrangements
Complete VDJH rearrangements were amplified using two
multiplexed tubes containing VH-family specific primers for FR1
and FR3 regions with a JH consensus primer according to the
BIOMED-2 Concerted Action [25]. All reactions were carried out
in 25 mL containing 100 ng of DNA samples and 10 pm of each
primer. Then the clonal nature of the PCR fragments was
confirmed by Gene-Scanning analysis in an ABI 3130 DNA
Sequencer (Applied Biosystems, Foster City, CA, USA).
Copy number abnormalities (CNA) studies
DNA was isolated from CD138++ (n = 3) and CD138low (n = 3)
RPMI-8226 cells using GenElute Mammalian Genomic DNA
Miniprep Kit (Sigma-Aldrich) following the manufacturer’s
protocol. The detection of CNA was investigated using the
CytoScan HD array (Affymetrix, Santa Clara, CA, USA) which
includes more than 2.6 million copy number markers and 750.000
SNPs. Briefly, genomic DNA was digested with Nsp I restriction
endonuclease, ligated to adaptors that recognize the cohesive four
base pair overhangs and amplified by PCR. PCR product was
purified and fragmented with DNAse I and then end-labeled using
terminal deoxynucleotidyl transferase and hybridized to the
CytoScan HD array. The arrays were processed using the Fluidics
Table 1. Genes differentially expressed in CD138low RPMI-8226 versus CD138++ RPMI-8226 cells.
Probe set Fold change Gene Title Gene Symbol
8118548 2,25 major histocompatibility complex, class II, DR alpha HLA-DRA
7952335 2,29 small nucleolar RNA, C/D box 14E SNORD14E
8179481 2,37 major histocompatibility complex, class II, DR alpha HLA-DRA
8178193 2,96 major histocompatibility complex, class II, DR alpha HLA-DRA
8101126 4,14 chemokine (C-X-C motif) ligand 10 CXCL10
doi:10.1371/journal.pone.0092378.t001
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Figure 3. Proliferation of CD138++ and CD138low subpopulations. (A) Left: Cell percentage of CD138++ and CD138low RPMI-8226 or NCI-H929
cells in G0-G1, S and G2-M phases. The results are expressed as the means 6 SEM of at least three independent experiments. Right: Representative
DRAQ5 histograms for each indicated population. (B) Left: Relative Ki-67 MFI of CD138++ and CD138low RPMI-8226 and NCI-H929 cells with respect to
isotype control. Results are expressed as the means 6 SEM of three independent experiments. Right: Representative Ki-67 histograms for each
indicated population. Filled histograms (isotype control); open histograms (Ki-67).
doi:10.1371/journal.pone.0092378.g003
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Station 450, GeneChip Scanner 3000 7 G and AGCC (Affyme-
trixGeneChip Command Console Software).
For the analysis we employed the Affymetrix Chromosome
Analysis Suite (ChAS) Software v2.0 and Nexus Copy Number
Software Version 7.0 (BioDiscovery, El Segundo, CA, USA). The
complete data set was analyzed by visual inspection using ChAS
software. CNA were reported when the three following criteria
were achieved: minimum of 50 markers per segment, 200 Kb
minimum genomic sizes and 50% overlap with known copy
number variants (Database of Genomic Variants). Nexus software
was employed to obtain the presented Figures. All microarray data
have been deposited with the Gene Expression Omnibus
(accession number GSE49483).
Myeloma xenografts
For serial engrafting assays, either sorted CD138++ or CD138low
RPMI-8266 cells were subcutaneously inoculated into the right
flank of 6–7 week old female CB17-SCID mice (Charles River,
Spain) as previously described [26] to generate primary tumors (5
mice were inoculated per group with 36104 cells) and subsequently
cells isolated from primary tumors were serially transplanted into
new mice to generate secondary tumors (6 mice were inoculated per
group with 36106 cells). Caliper measurement of the tumor
diameters were performed three times per week and the tumor
volume was estimated as the volume of an ellipse using the following
formula: V=4/3 p 6 (a/2) 6 (b/2)2, where ‘‘a’’ and ‘‘b’’
correspond to the longest and shortest diameter, respectively.
Animals were sacrificed when their tumor diameter was#2 cm. To
investigate the phenotype of the generated tumors, we mechanically
Figure 4. Study of aldehyde dehydrogenase expression and drug sensitivity in CD138++ and CD138low subpopulations. (A) Single
parameter histograms illustrating the expression of ALDH in the presence or absence of the ALDH inhibitor DEAB (diethylaminobenzaldehyde) in
CD138++ and CD138low subpopulations of the cell lines RPMI-8226, NCI-H929 and MM1S (B) Sorted CD138++ or CD138low RPMI-8226 cells were
incubated in the absence (control) or presence of bortezomib (10 nM), melphalan (10 mM) or doxorubicin (250 nM) for 24 and 48 hours. After the
incubation time, cell viability was measured by MTT assay and the percentage of cell viability was calculated considering control as 100%. Results are
the means 6 SEM of at least three independent experiments.
doi:10.1371/journal.pone.0092378.g004
CD138 in Multiple Myeloma Cell Lines
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e92378
minced and filtered the tumors through 40 mm cell-strainers and
stained the obtained cell suspension with CD38-FITC plus CD138-
APC. 7AAD was used also to exclude dead cells.
Statistical analysis
Statistical analysis was performed using the SPSS-20.0 software
(SPSS, Chicago, IL, USA). Significant differences between groups
were assessed by Mann-Whitney U tests.
Results
CD138 expression in MM cell lines
We analyzed the phenotypic profile of eight MM cell lines
(RPMI-8226, MM1S, NCI-H929, U266, RPMI-LR5, MM1R,
U266-LR7 and U266-Dox4) to investigate the presence of
CD1382 or CD138low MM cells. All eight MM cell lines
contained two populations with different intensity of CD138
expression: one with bright staining (CD138++) that represented
Figure 5. Tumorigenic potential of CD138++ and CD138low subpopulations. (A) 36104 sorted CD138++ RPMI-8226 or CD138low RPMI-8226
cells were subcutaneously injected into CB17-SCID mice to generate primary tumors. Subsequently, 36106 cells isolated from selected primary
tumors were serially transplanted into new CB17-SCID mice to generate secondary tumors. The engraftment efficacy is indicated in each case. (B, C)
Tumor growth curves for CB17-SCID mice that developed measurable primary and secondary tumors. Growth curves represent tumor volumes
(means 6 SEM; n = 4–6) until the time point in which the first mouse in every group is sacrificed.
doi:10.1371/journal.pone.0092378.g005
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around 95–99% of all MM cells and a minor fraction showing dim
intensity (CD138low) that represented 1–5% (Figure 1A). No
differences were observed between these two populations regard-
ing other myeloma-related markers (CD38, CD45, CD56) and
both subpopulations were negative for the B-cell markers CD19,
CD20 and CD27 (Figure 1B). Moreover, in one cell line (RPMI-
8226) we analyzed the morphology of both subpopulations and
CD138low cells did not display different morphological character-
istics as compared to CD138++ cells (Figure S2). The expression of
CD138 was also explored by alternative techniques in two cell
lines (RPMI-8226 and NCI-H929). By qRT-PCR, no differences
were noted in CD138 mRNA levels between CD138++ and
CD138low RPMI-8226 cells (Figure 1C). However, by immuno-
cytochemistry a clear higher surface staining for CD138 in the
CD138++ subpopulation from both RPMI-8226 and NCI-H929
cells was found (Figures 1D–K) in accordance with the results
observed by flow cytometry. It should be noted that neither
CD138++ nor CD138low subpopulations contained apoptotic
nuclei (Figures 1D–K) and in fact both were negative for
annexin-V and 7AAD (Figure S3).
Genomic characterization of CD138++ and CD138low
subpopulations
To confirm the clonal relationship among CD138++ and
CD138low subpopulations, we analyzed the IGH rearrangements
of CD138++ RPMI-8226 cells (n = 2) and CD138low RPMI-8226
cells (n = 2). The monoclonal VDJH rearrangement was present in
all samples with the same pattern and size in the GeneScan
analysis (340 bp for FR1 and 131 bp for FR3), demonstrating a
common clonal origin of CD138++ and CD138low subpopulations.
To explore if phenotypically distinct CD138++ and CD138low
subpopulations had different genomic changes, we comparatively
studied CNA of CD138++ RPMI-8226 (n= 3) and CD138low
RPMI-8226 (n= 3) subpopulations, but no relevant differences
were observed (Figure 2). Finally, we compared the gene
expression profile of CD138++ and CD138low RPMI-8226 cells.
As shown in Table 1, only three genes (HLA-DRA, SNORD14E
and CXCL10) were differentially expressed between the two
populations, and specifically overexpressed in the CD138low cells.
Proliferation of CD138++ and CD138low subpopulations
We analyzed the cell cycle of CD138++ and CD138low
subpopulations in two cell lines (RPMI-8226 and NCI-H929)
and we observed that none of them is truly quiescent, although the
CD138low subpopulation shows a numerically -not significantly-
lower percentage of cells in G2-M phase as compared to the
CD138++ subpopulation (Figure 3A). These results were further
confirmed by Ki-67 staining. Both CD138++ and CD138low
subpopulations in RPMI-8226 and NCI-H929 cell lines showed
considerable and similar levels of Ki-67 (Figure 3B).
Study of ALDH expression and drug sensitivity in
CD138++ and CD138low subpopulations
Since drug resistance is a hallmark of stem cells [27,28] we next
studied the expression of the drug resistance and stem cell-
associated marker ALDH [29] in CD138++ and CD138low cells. In
three different cell lines (RPMI-8226, NCI-H929 and MM1S) the
expression of ALDH was barely noted in both CD138++ and
CD138low subpopulations with no differences between them
(Figure 4A). To compare the sensitivity of CD138++ and CD138low
cells to different anti-myeloma drugs we sorted both subpopula-
tions from the RPMI-8226 cell line and incubated the two
subpopulations in the absence (control) or presence of bortezomib,
melphalan or doxorubicin. No differences in the sensitivity of
CD138++ and CD138low cells to any of the tested drugs was found
(Figure 4B).
Tumorigenic potential of CD138++ and CD138low
subpopulations
We compared the engrafting potential of CD138++ and
CD138low RPMI-8226 cells in a serial transplantation assay in
CB17-SCID mice. Initially, the same number (36104) of sorted
CD138++ and CD138low cells were subcutaneously injected into
CB17-SCID mice to generate primary tumors, and subsequently
the cells isolated from primary tumors were serially transplanted
into new mice (36106 cells/mouse) to generate secondary tumors
(Figure 5A). No significant differences were found for primary and
secondary tumors neither in the growth curves (Figures 5B–C) nor
in the engrafting capacity (Figure 5A).
CD138++ cells give rise to CD138low cells and vice versa
Since differentiation potential is a characteristic of stem cells
[30], we wanted to know if CD138++ cells give rise to CD138low
cells or vice versa. To this aim, we analyzed the phenotype of the
tumors derived from purified CD138++ RPMI-8226 or CD138low
RPMI-8226 cells. As shown in Figure 6A, primary and secondary
tumors derived from both populations contained similar percent-
ages of CD138++ and CD138low/- cells, indicating that, in vivo, each
population is able to give rise to the other. To confirm these results
and to dismiss that they are due to contamination of the sorted
populations injected into the mice, we performed an in vitro
experiment of single-cell sorting. Thus, we single-sorted either
CD138++ or CD138low RPMI-8226 cells into 96 multiwell plates
(1 cell/well) and allowed them to expand for a period of time
between 25–37 days. We found a higher number of clones derived
from CD138++ subpopulation (13 clones out of 96) as compared to
CD138low subpopulation (6 clones out of 96). The phenotypic
analysis of all clones showed that, independently of the initiating
cell (CD138++ or CD138low), every clone contained CD138++ and
CD138low cells (Figures 6B and 6C). Overall, these results indicate
that CD138++ cells give rise to CD138low cells and vice versa.
Discussion
Although the presence of clonogenic cells in MM was described
more than 30 years ago [2] the phenotype of the resistant putative
MM-CSC is still a matter of debate. In this work, we have focused
on myeloma cells with low expression of the maturation associated
surface marker CD138. Our results show that the minor
subpopulation of CD138low cells contained in MM cell lines does
not differ from the major CD138++ subpopulation regarding
phenotypic, genomic and functional features.
An immature phenotype is a typical hallmark of cancer stem
cells [31]. However, in MM there is still an ongoing controversy
Figure 6. CD138++ cells give rise to CD138low cells and vice versa. (A) The graphs represent the percentage of CD38++CD138++ and
CD38++CD138low/- cells of primary and secondary CD138++ RPMI-8226 and CD138low RPMI-8226 derived tumors. Results are expressed as the means6
SEM (n = 4-6). A representative dot plot for every group of tumors is shown and the percentage of CD38++CD138++ and CD38++CD138low/- is indicated
in each case (B, C) Phenotype of each individual clone derived from CD138++ RPMI-8226 or CD138low RPMI-8226 cells. The percentage of CD138++ and
CD138low cells is indicated in each dot plot.
doi:10.1371/journal.pone.0092378.g006
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with respect to the phenotype of MM-CSC. Thus, some authors
have suggested that MM-CSC are CD138 negative [9,10,11],
whereas others have demonstrated the existence of CD138 positive
plasma cells with stem cell properties [12,13,14,32]. Traditionally,
a better understanding of cancer stem cell properties has been
possible, in part, by analyzing cell lines obtained from different
types of tumors [33,34,35]. Here, we investigated in a panel of
eight MM cell lines for the presence of a CD138low/- population
and we analyzed its biological characteristics. As previously
suggested by other authors [9,16,36,37] we confirmed that all
cell lines contain a minor subpopulation of CD138low cells.
However, it has been recently described that infraexpression of
CD138 in MM cells may be an artifact due to apoptotic induction
[17]. Our results show that the CD138low subpopulation is viable
as demonstrated by DAPI-nuclear as well as Annexin-V/7ADD
staining.
The presence of CD138low/- cells in myeloma is intriguing
because it could imply a less differentiated state. In fact, it has been
previously reported that the interaction of myeloma cells with
different types of cells of the bone marrow microenvironment
promotes a reduction of CD138 expression, a less differentiated
morphology and an increase of the B-cell associated transcription
factor, Bcl6 [15,16,38]. Here, we have detected the presence of
myeloma cells with low expression of CD138 in the absence of
bone marrow microenvironment cells and under these circum-
stances, the population of CD138low cells does not seem to
represent a more immature compartment since it does not express
the B-cell associated markers CD19, CD20 and CD27 and it does
not show a less differentiated morphology. Moreover, VDJH
rearrangement analysis, CNA analysis and gene expression
profiling did not show relevant differences between CD138++
and CD138low cells. In fact, the absence of substantial differences
in the gene expression profiling of both populations has also been
revealed using single molecule microarray in a recent study [39].
Furthermore, the higher or lower surface expression of CD138 in
MM cells seems to be regulated at the protein rather than
transcriptional level, as demonstrated by similar CD138 mRNA
levels found in the two subpopulations. It should be noted that our
in vitro and in vivo results demonstrate the bidirectional origin of the
two populations since CD138++ cells give rise to CD138low cells
and vice versa. These data suggest a dynamic between the two
phenotypic subpopulations that tend to equilibrium, and could be
responsible of the heterogeneity typically found in MM cells, as
previously demonstrated through statistical modeling in breast
cancer cell lines [33]. In fact, it has been demonstrated in
myeloma patient samples the presence of interconvertible pheno-
typic and functional states responsible of myeloma-propagating
activity and drug resistance [40].
Apart from the immature phenotype, other hallmarks of normal
and cancer stem cells are quiescence, chemoresistance and
potential to self-renew [41,42]. Here, we have compared the cell
cycle of CD138++ and CD138low cells and found that none of them
is quiescent as demonstrated by a considerable percentage of cells
($25%) in the proliferative phases (S and G2-M) of the cell cycle.
This was further confirmed by substantial expression of the
proliferation-associated marker Ki-67. Nevertheless, we observed
a numerically -not significantly- lower percentage of cells in G2-M
phase in CD138low cells as compared to the CD138++ fraction that
could be the cause of the lower number of clones expanded in vitro
from the CD138low subpopulation. These results are in line with
previous data by Fuhler and col. in RPMI-8226 cells [16], but
differ from those by Matsui and col. who found that the CD138
negative subpopulation within RPMI-8226 and NCI-H929 cell
lines is mainly quiescent (.98% cells in G0–G1) [10], but
paradoxically express higher levels of Ki-67 than CD138 positive
cells [9]. The proliferation rate of CD138+ and CD1382 myeloma
cells has also been described in primary patient samples with
discordant results. Reid and col. observed a higher proliferation
rate of CD38++CD1382 myeloma cells as compared with
CD38++CD138+ myeloma cells [43], whereas Chaidos and col.
identified a so-called pre-plasma cell compartment
(CD38++CD1382) that is relatively quiescent [40].
The chemoresistance of cancer stem cells is mainly associated to
their specific properties such as quiescence [28], expression of
multidrug resistance efflux pumps [44] and expression of
detoxifying enzymes [45]. Here, we investigated the expression
of the detoxifying enzyme ALDH and, in contrast to previous
observations [10], we have not found higher ALDH expression in
CD138low cells as compared to CD138++ cells. Moreover,
CD138++ and CD138low RPMI-8226 cells displayed similar
sensitivity to different antimyeloma drugs. Overall, these results
indicate that the CD138low subpopulation within myeloma cell
lines does not represent a specific chemoresistant compartment. In
fact, our results support recent data by Jakubikova and col. who
found a lack of correlation between the drug resistant ‘‘side
population’’ and CD138-/low subpopulations in MM cell lines [37].
As previously mentioned, the potential to self-renew is another
hallmark of stem cells [41,42]. This specific property is linked to
the potential of stem cells to serially engraft into immunocompro-
mised mice [46]. In MM, the first evidence of self-renewal pointed
to the capacity of circulating cells to engraft into NOD-SCID mice
[47]. Nevertheless, later studies have been controversial, with some
authors demonstrating the tumorigenic potential of post-germinal
center memory B-cells [9,10] while others of MM plasma cells
[12,14,32,40,48,49,50]. Here, we demonstrated in a serial
transplantation assay in SCID mice that both CD138++ and
CD138low RPMI-8226 cells have tumorigenic and self-renewal
potential. These results are in line with previous studies in which
the tumorigenic potential of CD192CD38+CD138+ and
CD192CD38+CD1382 primary plasma cells was compared and
both populations were able to engraft into immunocompromised
mice [32,40].
In conclusion, our results show that the minor CD138low
subpopulation in MM cell lines does not represent an immature B-
cell compartment and has similar genomic and functional profile
as compared to the major CD138++ fraction. Both CD138++ and
CD138low subpopulations have self-renewal potential, similar drug
sensitivity and are phenotypically interconvertible. Therefore,
these results highlight the need to explore new and more reliable
markers able to discriminate true clonogenic myeloma cells.
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Figure S1 Gating strategy for sorting CD138++ and
CD138low subpopulations in RPMI-8226 cells. Top panel:
viable cells were gated as 7AAD-ve (R1) and subsequently debris
were eliminated by scatter properties (R2). Finally, the lowest and
highest 5% CD138-expressing cells were gated on R2. Bottom
panel: CD138++ and CD138low sorted cells had a final purity
.95% in the post-sort analysis.
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Figure S2 Morphology of CD138++ and CD138low RPMI-
8226 cells. May-Gru¨nwald-Giemsa staining of sorted CD138++
and CD138low RPMI-8226 cells. Scale bar = 10 mm.
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Figure S3 Analysis of apoptosis in CD138++ and
CD138low subpopulations in RPMI-8226, NCI-H929,
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MM1S and U266 cell lines. Non-apoptotic cells were gated as
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cells.
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